Doxorubicin Hydrochloride Injection, Solution
Product Images NDC 0143-9088

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 0143-9088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Doxorubicin Liquid Novaplus 1)

FDA Label Image

Fig. 1 (Doxorubicin Liquid Novaplus 2)

Fig. 1 (Doxorubicin   Liquid   Novaplus 2)
The text is a figure showing a meta-analysis of disease-free survival with a hazard ratio, trial names, and a comparison between doxo based therapy and CMF. It also includes a boundary of non-inferiority with CMF.*
FDA Label Image

Fig.2 (Doxorubicin Liquid Novaplus 3)

Fig.2 (Doxorubicin   Liquid   Novaplus 3)
This appears to be a figure that shows a meta-analysis of Overall Survival, likely for cancer treatment. It includes different trials and the Hazard Ratio (a measure of treatment effectiveness) for each trial, along with confidence intervals. The figure compares Doxo-based treatments (used in six studies) to CMF treatments. The x-axis shows time, and the y-axis shows the Hazard Ratio.*
FDA Label Image

Vial (Doxorubicin Liquid Novaplus 4)

Vial (Doxorubicin   Liquid   Novaplus 4)
This is a description of a medication called DOXOrubicin. It is a sterile isotonic solution that is used for intravenous (IV) use only. The solution comes in a 5 mL single-dose vial and each mL contains 2mg of Doxorubicin HCI, sodium chloride, and water for injection. The usual dosage is included in the package insert. The medication is refrigerated and protected from light in the carton until it is time for use. The drug is preservative-free, and any unused portion should be discarded. The warning is provided that severe cellulitis, vesication, and tissue necrosis will occur if doxorubicin is extravasated during administration. This medication is distributed by Hikma Pharmaceuticals USA Inc. in Berkeley Heights, NJ.*
FDA Label Image

Vial (Doxorubicin Liquid Novaplus 5)

Vial (Doxorubicin   Liquid   Novaplus 5)
This is a description of a medication named Doxorubicin HCI, with a National Drug Code of 0143-9089-01, which comes in a 10mL Single Dose Vial that contains 2mg of Doxorubicin and other substances like Sodium Chloride and water. The medication should be stored in a refrigerator between 2°C to 8°C, protected from light until usage, and must be discarded if unused. The product is distributed by Hikma Pharmaceuticals USA under the brand novaplus™. The package of the product includes a warning about the risks of extravesation, which may cause severe cellulitis, vesiculation, and tissue necrosis. The image replacement text () includes some errors and typos.*
FDA Label Image

Vial (Doxorubicin Liquid Novaplus 6)

Vial (Doxorubicin   Liquid   Novaplus 6)
This text describes a medication named DOXOrubicin HCI Injection, USP, with a strength of 50mg per 25mL solution. The medication is stored in a 25mL vial and is intended for intravenous use only. The solution is sterile and isotonic and contains 2 mg Doxorubicin HCI, USP, Sodium Chloride, and Water for Injection, pH adjusted to 3 using Hydrochloric Acid. The medication should be stored in the refrigerator between 2°C to 8°C( 36°F to 46°F) and protected from light. Severe cellulitis, vesication, and tissue necrosis can occur if extravasation of the medication during administration happens. It is manufactured by THYMOORGAN PHARMAZIE GrabH, Germany, and distributed by Hikma Pharmaceuticals USA Inc. The package insert contains complete prescribing information, including the usual dosage.*
FDA Label Image

Vial (Doxorubicin Liquid Novaplus 7)

Vial (Doxorubicin   Liquid   Novaplus 7)
This is a pharmaceutical product - DOXOrubicin HCI Injection, USP, indicated for intravenous use only. Each 100 mL contains 200 mg Doxorubicin HCI USP and is provided in a sterile, isotonic solution. It is recommended to be stored in a refrigerator at 2° to 8°C and protected from light. Severe cellulitis, vesication, and tissue necrosis may occur if doxorubicin is extravasated during administration. It is manufactured by THYMOORGAN PHARMAZIE GmbH, Germany, and distributed by Hikma Pharmaceuticals USA Inc, Berkeley Heights, NJ 07922. Complete prescribing information can be found in the package insert. The NDC number for this product is 0143-8091-01.*
FDA Label Image

Representative Serialization Image (Doxorubicin Liquid Novaplus 8)

Representative Serialization Image (Doxorubicin   Liquid   Novaplus 8)
This is a product identification tag containing a Global Trade Item Number (GTIN) of 0301234567896, a serial number (SN) of 1234567890123, an expiration date (EXP) of MMMYYYY (month and year), and a lot number (LOT) of ABCDE12345.*
FDA Label Image

Representative Serialization Image (Doxorubicin Liquid Novaplus 9)

Representative Serialization Image (Doxorubicin   Liquid   Novaplus 9)
This text contains product and batch identification information. Specifically, the first section "T Lot" may indicate a lot number or tracking identification code. The following "ABCDE12345" may represent a product code or serial number, while "EXP MMMYYYY" likely represents an expiration date with month and year. The subsequent "GTIN 00301234567896" could signify a Global Trade Item Number, and "SN 12345678901234" may represent a unique serial number for the product. Based on this information, a product can be traced and identified for quality control or recall purposes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.